146 related articles for article (PubMed ID: 33217678)
1. Genetic heterogeneity and predictive biomarker for pulmonary sarcomatoid carcinomas.
Qin J; Chen B; Li C; Yan J; Lu H
Cancer Genet; 2021 Jan; 250-251():12-19. PubMed ID: 33217678
[TBL] [Abstract][Full Text] [Related]
2. Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma.
Liu X; Wang F; Xu C; Chen X; Hou X; Li Q; Li P; Xie Z; Liu Y; Chang L; Guan Y; Zhang X; Yang L; Wang H; Yi X; Zhang J; Xia X; Moran C; Chen L
Oncogene; 2021 Jan; 40(4):821-832. PubMed ID: 33273725
[TBL] [Abstract][Full Text] [Related]
3. Genomic Landscape of Pulmonary Sarcomatoid Carcinoma.
Kwon HJ; Lee S; Han YB; Lee J; Kwon S; Kim H; Chung JH
Cancer Res Treat; 2024 Apr; 56(2):442-454. PubMed ID: 37973906
[TBL] [Abstract][Full Text] [Related]
4. Mutation landscape and tumor mutation burden analysis of Chinese patients with pulmonary sarcomatoid carcinomas.
Liang X; Li Q; Xu B; Hu S; Wang Q; Li Y; Zong Y; Zhang S; Li C
Int J Clin Oncol; 2019 Sep; 24(9):1061-1068. PubMed ID: 31065835
[TBL] [Abstract][Full Text] [Related]
5. New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles.
Nakagomi T; Goto T; Hirotsu Y; Shikata D; Yokoyama Y; Higuchi R; Amemiya K; Okimoto K; Oyama T; Mochizuki H; Omata M
Oncotarget; 2018 Feb; 9(12):10635-10649. PubMed ID: 29535832
[TBL] [Abstract][Full Text] [Related]
6. The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients.
Zhou F; Huang Y; Cai W; Li J; Su C; Ren S; Wu C; Zhou C
Lung Cancer; 2021 Mar; 153():66-72. PubMed ID: 33454519
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
[TBL] [Abstract][Full Text] [Related]
8. Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas.
Lococo F; Torricelli F; Rossi G; Alifano M; Damotte D; Rapicetta C; Tamagnini I; Cavazza A; Piana S; Galeone C; Paci M; Ciarrocchi A
Lung Cancer; 2017 Nov; 113():93-101. PubMed ID: 29110857
[TBL] [Abstract][Full Text] [Related]
9. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
[TBL] [Abstract][Full Text] [Related]
10. High programmed death ligand 1 expression in carcinomatous components predicts a poor prognosis in pulmonary pleomorphic carcinoma.
Noguchi M; Menju T; Nakajima N; Yoshizawa A; Ohsumi A; Nakajima D; Hamaji M; Haga H; Date H
Surg Today; 2022 Jul; 52(7):1090-1095. PubMed ID: 35041089
[TBL] [Abstract][Full Text] [Related]
11. Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma.
Lococo F; Gandolfi G; Rossi G; Pinto C; Rapicetta C; Cavazza A; Cesario A; Galeone C; Paci M; Ciarrocchi A
J Thorac Oncol; 2016 Aug; 11(8):1282-1292. PubMed ID: 27156442
[TBL] [Abstract][Full Text] [Related]
12. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Liu X; Jia Y; Stoopler MB; Shen Y; Cheng H; Chen J; Mansukhani M; Koul S; Halmos B; Borczuk AC
J Clin Oncol; 2016 Mar; 34(8):794-802. PubMed ID: 26215952
[TBL] [Abstract][Full Text] [Related]
13. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
14. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance and Next-Generation Sequencing of Chinese Pulmonary Sarcomatoid Carcinoma.
Li X; Wang D; Zhao Q; Ren D; Ren F; Chen G; Liu H; Chen J
Sci Rep; 2017 Jun; 7(1):3947. PubMed ID: 28638113
[TBL] [Abstract][Full Text] [Related]
16.
Wu X; Huang Y; Li Y; Wang Q; Wang H; Jiang L
Ann Nucl Med; 2019 Sep; 33(9):647-656. PubMed ID: 31165974
[TBL] [Abstract][Full Text] [Related]
17. Hepatic Sarcomatoid Carcinoma Is an Aggressive Hepatic Neoplasm Sharing Common Molecular Features With Its Conventional Carcinomatous Counterparts.
Yoshuantari N; Jeng YM; Liau JY; Lee CH; Tsai JH
Mod Pathol; 2023 Jan; 36(1):100042. PubMed ID: 36788061
[TBL] [Abstract][Full Text] [Related]
18. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
Mignard X; Ruppert AM; Antoine M; Vasseur J; Girard N; Mazières J; Moro-Sibilot D; Fallet V; Rabbe N; Thivolet-Bejui F; Rouquette I; Lantuejoul S; Cortot A; Saffroy R; Cadranel J; Lemoine A; Wislez M
J Thorac Oncol; 2018 Dec; 13(12):1962-1967. PubMed ID: 30149144
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
Sabari JK; Leonardi GC; Shu CA; Umeton R; Montecalvo J; Ni A; Chen R; Dienstag J; Mrad C; Bergagnini I; Lai WV; Offin M; Arbour KC; Plodkowski AJ; Halpenny DF; Paik PK; Li BT; Riely GJ; Kris MG; Rudin CM; Sholl LM; Nishino M; Hellmann MD; Rekhtman N; Awad MM; Drilon A
Ann Oncol; 2018 Oct; 29(10):2085-2091. PubMed ID: 30165371
[TBL] [Abstract][Full Text] [Related]
20. Aligning digital CD8
Conde E; Caminoa A; Dominguez C; Calles A; Walter S; Angulo B; Sánchez E; Alonso M; Jimenez L; Madrigal L; Hernando F; Sanz-Ortega J; Jimenez B; Garrido P; Paz-Ares L; de Castro J; Hernandez S; Lopez-Rios F
Histopathology; 2018 Jan; 72(2):270-284. PubMed ID: 28815764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
